查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1658719

全球單株抗體 (mAb) 治療市場按來源、應用/治療領域、分銷管道、地區、趨勢分析、競爭格局、預測（2019-2031 年）

Monoclonal Antibody Therapeutics Market, By Source; By Application/Therapy Area; By Distribution Channel, By Region, Global Trend Analysis, Competitive Landscape & Forecast, 2019-2031
出版日期: | 出版商: Blueweave Consulting | 英文 512 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

由於慢性病發病率不斷上升、生物製藥研發項目投入不斷增加以及 mAb 治療應用不斷擴大，全球單株抗體 (mAb) 治療市場正在蓬勃發展。

預計 2024 年全球單株抗體 (mAb) 治療市場規模將達 2,732 億美元。預計到 2031 年將成長一倍以上，達到 5,593 億美元，在 2025-2031 年預測期內的複合年成長率為 11.2%。癌症和心血管疾病等慢性疾病的增加正在推動對生技藥品的需求，尤其是標靶治療，例如單株抗體。患者和醫療保健提供者對 mAb 治療效果的認知不斷提高也是支持全球單株抗體 (mAb) 治療市場的一個主要促進因素。由免疫動物的細胞株或克隆產生的單株抗體已成為現代醫學必不可少的物質。其針對特定疾病標記或病原體的能力鞏固了其廣泛的適用性。隨著禮來公司的 bebtelovimab（已獲得 FDA 緊急使用授權）等 mAb治療方法的開發，COVID-19 疫情進一步加速了市場發展勢頭。 mAb療法具有特異性、有效性和給藥方便等優點，已導致許多產品的上市和核准，目前已有超過100種mAb核准。片段抗體、雙特異性抗體和其他先進療法等各領域的持續創新有望擴大治療應用。此外，主要參與企業的策略性舉措繼續推動全球單株抗體（mAb）治療市場的擴張。

機會－擴大單株抗體的全球取得管道

單株抗體 (mAb) 徹底改變了癌症、自體免疫疾病和 COVID-19 和 HIV 等感染疾病的治療方法，但其可及性仍然有限，全球 85% 的人口居住在中低收入國家，而 80% 的銷售額集中在高所得地區。為了解決這一差距，IAVI和Wellcome等全球衛生組織已發出行動呼籲，敦促相關利益者提高對單株抗體拯救生命潛力的認知，擴大許可，降低生產成本，並開發永續取得的創新經營模式。融合瘤技術、電融合、基因改造動物和基於核酸的 mAb 的進步透過提高特異性、降低免疫抗原性和簡化生產來提高生產力。這些創新可以實現更精確的治療，並且副作用更少，針對癌症和其他有害細胞的特異性抗原。隨著 mAb 市場的成長，提高可得性對於確保這些創新療法公平分配和最大限度地發揮其在世界範圍內的影響至關重要。

地緣政治緊張局勢加劇對全球單株抗體 (mAb) 治療市場的影響

不斷加劇的地緣政治緊張局勢可能會阻礙全球單株抗體（mAb）治療市場的成長。潛在的干擾因素，包括貿易限制、關稅提高、供應鏈脆弱性和法規環境波動，可能會阻礙 mAb 的生產和分銷，從而可能增加成本並限制患者獲得藥物的機會。相反，這種緊張局勢可能促使各國政府優先考慮衛生安全、擴大國內生物製藥生產能力、加強本土生產、減少對進口的依賴，並鼓勵供應鏈的彈性和替代製造策略的創新。因此，雖然地緣政治不確定性帶來了重大挑戰，但也可能刺激進步並再形成全球 mAb 治療市場的未來軌跡。

北美引領全球單株抗體（mAb）治療市場

北美引領全球單株抗體（mAb）治療市場，這主要是由於高昂的醫療成本，尤其是美國。儘管美國的醫療保健支出遠遠超過其他國家，但這種支出並沒有轉化為健康狀況的相應改善。高價格和服務利用率導致美國醫療費用飆升。同時，由於創新研究、技術進步和醫療服務需求的不斷成長，加拿大的醫療保健產業正在呈現強勁成長。加拿大醫療保健格局的動態發展進一步增強了北美市場的整體主導地位和 mAb 治療領域的成長潛力。為體現這一市場動態，2022 年 1 月，葛蘭素史克和 Vir Biotechnology 與美國政府簽署了一項重要協議，以購買額外的 sotrovimab（一種獲批用於早期治療 COVID-19 的 mAb）。

本報告對全球單株抗體（mAb）治療市場進行了深入分析，並提供了有關成長潛力和未來趨勢的資訊。它還分析了市場的成長動力、挑戰和競爭動態。

目錄

第1章 調查框架

第 2 章執行摘要

第 3市場考察。

  • 最終用戶價值鏈分析
  • DROC 分析
    • 成長動力
      • 慢性病增加
      • 增加對單株抗體研發專案的投資
      • 擴充應用
    • 限制因素
      • mAb治療成本高
      • 嚴格的監管要求
    • 機會
      • 新型 mAb治療方法的開發
      • 個人化醫療的採用日益增多
    • 任務
      • 生物相似藥的競爭
      • 潛在的副作用
  • 科技進步/最新發展
  • 法規結構
  • 波特五力分析

第 4 章。

5. 全球單株抗體 (mAb) 治療市場：定價分析

6. 全球單株抗體 (mAb) 治療市場：區域分析

  • 全球單株抗體 (mAb) 治療市場，區域分析（2024 年）
  • 全球單株抗體 (mAb) 治療市場吸引力分析（2024-2031 年）

7. 全球單株抗體 (mAb) 治療市場概述

  • 市場規模及預測（2019-2031）
    • 金額
  • 市場佔有率和預測
    • 按產地
      • 人類
      • 人性化
      • 嵌合體
      • 鼠
    • 按應用/治療領域
      • 瘤
      • 自體免疫疾病
      • 感染疾病
      • 血液系統疾病
      • 心血管疾病
      • 其他
    • 按分銷管道
      • 醫院
      • 零售藥局
      • 網路藥局
    • 按地區
      • 北美洲
      • 歐洲
      • 亞太地區
      • 拉丁美洲
      • 中東和非洲

8. 北美單株抗體 (mAb) 治療市場

  • 市場規模及預測（2019-2031）
    • 金額
  • 市場佔有率和預測
    • 按產地
    • 按應用
    • 按分銷管道
    • 按國家
      • 美國
      • 加拿大

9. 歐洲單株抗體 (mAb) 治療市場

  • 市場規模及預測（2019-2031）
    • 金額
  • 市場佔有率和預測
    • 按產地
    • 按應用
    • 按分銷管道
    • 按國家
      • 德國
      • 英國
      • 義大利
      • 法國
      • 西班牙
      • 比利時
      • 俄羅斯
      • 荷蘭
      • 歐洲其他地區

10. 亞太地區單株抗體 (mAb) 治療市場

  • 市場規模及預測（2019-2031）
    • 金額
  • 市場佔有率和預測
    • 按產地
    • 按應用
    • 按分銷管道
    • 按國家
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳洲和紐西蘭
      • 印尼
      • 馬來西亞
      • 新加坡
      • 越南
      • 其他亞太地區

11. 拉丁美洲單株抗體 (mAb) 治療市場

  • 市場規模及預測（2019-2031）
    • 金額
  • 市場佔有率和預測
    • 按產地
    • 按應用
    • 按分銷管道
    • 按國家
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 其他拉丁美洲國家

12. 中東和非洲單株抗體 (mAb) 治療市場

  • 市場規模及預測（2019-2031）
    • 金額
  • 市場佔有率和預測
    • 按產地
    • 按應用
    • 按分銷管道
    • 按國家
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 科威特
      • 南非
      • 奈及利亞
      • 阿爾及利亞
      • 其他中東和非洲地區

第13章 競爭格局

  • 主要企業及其產品列表
  • 全球單株抗體 (mAb) 治療市場佔有率分析（2024 年）
  • 競爭性基準化分析：根據業務參數
  • 重大策略發展（合併、收購、聯盟）

14. 地緣政治緊張局勢加劇對全球單株抗體 (mAb) 治療市場的影響

第 15 章 公司簡介（公司概況、財務矩陣、競爭格局、關鍵人員、主要競爭對手、聯繫、策略展望、SWOT 分析）

  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Johnson & Johnson Services, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Amgen Inc
  • Bristol Myers Squibb Company (US)
  • Merck & Co Inc
  • AstraZeneca plc
  • Sanofi
  • Bayer AG
  • Eli Lilly and Company
  • Thermo Fisher Scientific Inc
  • 其他知名公司

第16章 關鍵策略建議

第17章調查方法

簡介目錄
Product Code: BWC25080

Global Monoclonal Antibody (mAb) Therapeutics Market Zooming 2X to Touch USD 560 Billion by 2031

Global Monoclonal Antibody (mAb) Therapeutics Market is flourishing because of the rising incidence of chronic diseases, increasing investments in biopharma R&D programs, and the expanding therapeutic applications of mAbs.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global Monoclonal Antibody (mAb) Therapeutics Market size at USD 273.2 billion in 2024. During the forecast period between 2025 and 2031, BlueWeave expects Global Monoclonal Antibody (mAb) Therapeutics Market size to more than doubles at a robust CAGR of 11.2% reaching a value of USD 559.3 billion by 2031. The increasing prevalence of chronic diseases, including cancer and cardiovascular conditions, fuels demand for biologics like mAbs, particularly for targeted therapies. Growing awareness among both patients and healthcare providers regarding the efficacy of mAb treatments are also major driving forces behind the Global Monoclonal Antibody (mAb) Therapeutics Market. mAbs, generated from cell lines or clones derived from immunized animals, have become indispensable in modern medicine. Their ability to target specific disease markers and pathogens underpins their broad applicability. The COVID-19 pandemic, with the development of mAb treatments like Eli Lilly's bebtelovimab (which received FDA emergency use authorization), further accelerated the market momentum. The advantages of mAb therapies, including their specificity, effectiveness, and convenient delivery methods, have resulted in numerous product launches and approvals, with over 100 mAbs currently holding FDA approval. Ongoing innovations in various areas, such as antibody fragments, bispecific antibodies, and other advanced therapies, promises to broaden their therapeutic applications. Furthermore, strategic initiatives undertaken by key market players continue to propel the expansion of Global Monoclonal Antibody (mAb) Therapeutics Market.

Opportunity - Expanding Global Access to Monoclonal Antibodies

Monoclonal antibodies (mAbs) have revolutionized the treatment of cancers, autoimmune diseases, and infectious diseases like COVID-19 and HIV, but access remains limited, with 80% of sales concentrated in high-income regions while 85% of the global population resides in low- and middle-income countries. To address this gap, global health organizations such as IAVI and Wellcome have issued a call to action, urging stakeholders to raise awareness of mAbs' life-saving potential, expand their licensure, reduce production costs, and create innovative business models for sustainable access. Advancements in hybridoma technology, electrofusion, transgenic animals, and nucleic acid-based mAbs are enhancing production by improving specificity, reducing immunogenicity, and simplifying manufacturing. These innovations enable more precise treatments with fewer side effects, targeting specific antigens on cancer and other unwanted cells. As the mAb market grows, increasing accessibility will be crucial in ensuring these transformative therapies are equitably distributed, maximizing their global impact.

Impact of Escalating Geopolitical Tensions on Global Monoclonal Antibody (mAb) Therapeutics Market

Intensifying geopolitical tensions could disrupt the growth of Global Monoclonal Antibody (mAb) Therapeutics Market. Potential disruptions, including trade restrictions, increased tariffs, supply chain vulnerabilities, and fluctuating regulatory environments, could impede mAb production and distribution, potentially increasing costs and restricting patient access, while also negatively impacting international pharmaceutical collaborations and investments in biologic drug development. Conversely, these tensions may stimulate increased government focus on healthcare security and the development of domestic biopharmaceutical manufacturing capacity, potentially bolstering regional production, reducing import reliance, and fostering innovation in supply chain resilience and alternative manufacturing strategies. Thus, while geopolitical uncertainties pose significant challenges, they may also inadvertently drive advancements and reshape the future trajectory of Global mAb Therapeutics Market.

North America Leads Global Monoclonal Antibody (mAb) Therapeutics Market

North America commands the leading position in Global Monoclonal Antibody (mAb) Therapeutics Market, primarily fueled by substantial healthcare expenditures, particularly in the United States. While United States healthcare spending significantly outpaces that of other nations, this expenditure does not consistently translate into proportionally improved health outcomes. High service prices and utilization rates contribute to the escalating costs within the United States system. Concurrently, Canada's medical sector is experiencing robust growth, driven by innovative research, technological advancements, and increasing demand for healthcare services. This dynamic evolution of the Canadian healthcare landscape further strengthens North America's overall market dominance and growth potential in the mAb therapeutics arena. Illustrating this market activity, in January 2022, GSK and Vir Biotechnology secured a significant agreement with the United States government for the purchase of additional supplies of sotrovimab, a mAb authorized for early treatment of COVID-19.

Competitive Landscape

Major companies in Global Monoclonal Antibody (mAb) Therapeutics Market include F. Hoffmann-La Roche Ltd, Novartis AG, Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Amgen Inc, Bristol Myers Squibb Company (US), Merck & Co Inc, AstraZeneca plc, Sanofi, Bayer AG, Eli Lilly and Company, and Thermo Fisher Scientific Inc. The presence of high number of companies intensify the market competition as they compete to gain a significant market share. These companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches to further enhance their market share.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and Global Monoclonal Antibody (mAb) Therapeutics Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Monoclonal Antibody (mAb) Therapeutics Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Monoclonal Antibody (mAb) Therapeutics Market Insights

  • 3.1. End User Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing Prevalence of Chronic Diseases
      • 3.2.1.2. Growing Investments in (mAb) R&D Programs
      • 3.2.1.3. Expanding Applications
    • 3.2.2. Restraints
      • 3.2.2.1. High Cost of (mAb) Therapies
      • 3.2.2.2. Stringent Regulatory Requirements
    • 3.2.3. Opportunities
      • 3.2.3.1. Developing Novel (mAb) Therapies
      • 3.2.3.2. Growing Adoption of Personalized Medicines
    • 3.2.4. Challenges
      • 3.2.4.1. Competitions from Biosimilars
      • 3.2.4.2. Potential Side Effects
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Monoclonal Antibody (mAb) Therapeutics Market: Marketing Strategies

5. Global Monoclonal Antibody (mAb) Therapeutics Market: Pricing Analysis

6. Global Monoclonal Antibody (mAb) Therapeutics Market: Geography Analysis

  • 6.1. Global Monoclonal Antibody (mAb) Therapeutics Market, Geographical Analysis, 2024
  • 6.2. Global Monoclonal Antibody (mAb) Therapeutics, Market Attractiveness Analysis, 2024-2031

7. Global Monoclonal Antibody (mAb) Therapeutics Market Overview

  • 7.1. Market Size & Forecast, 2019-2031
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Source
      • 7.2.1.1. Human
      • 7.2.1.2. Humanized
      • 7.2.1.3. Chimeric
      • 7.2.1.4. Murine
    • 7.2.2. By Application/Therapy Area
      • 7.2.2.1. Oncology
      • 7.2.2.2. Autoimmune Diseases
      • 7.2.2.3. Infectious Diseases
      • 7.2.2.4. Hematological Disorders
      • 7.2.2.5. Cardiovascular Diseases
      • 7.2.2.6. Others
    • 7.2.3. By Distribution Channel
      • 7.2.3.1. Hospitals
      • 7.2.3.2. Retail Pharmacies
      • 7.2.3.3. Online Pharmacies
    • 7.2.4. By Region
      • 7.2.4.1. North America
      • 7.2.4.2. Europe
      • 7.2.4.3. Asia Pacific (APAC)
      • 7.2.4.4. Latin America (LATAM)
      • 7.2.4.5. Middle East and Africa (MEA)

8. North America Monoclonal Antibody (mAb) Therapeutics Market

  • 8.1. Market Size & Forecast, 2019-2031
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Source
    • 8.2.2. By Application
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. United States
      • 8.2.4.1.1. By Source
      • 8.2.4.1.2. By Application
      • 8.2.4.1.3. By Distribution Channel
      • 8.2.4.2. Canada
      • 8.2.4.2.1. By Source
      • 8.2.4.2.2. By Application
      • 8.2.4.2.3. By Distribution Channel

9. Europe Monoclonal Antibody (mAb) Therapeutics Market

  • 9.1. Market Size & Forecast, 2019-2031
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Source
    • 9.2.2. By Application
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
      • 9.2.4.1. Germany
      • 9.2.4.1.1. By Source
      • 9.2.4.1.2. By Application
      • 9.2.4.1.3. By Distribution Channel
      • 9.2.4.2. United Kingdom
      • 9.2.4.2.1. By Source
      • 9.2.4.2.2. By Application
      • 9.2.4.2.3. By Distribution Channel
      • 9.2.4.3. Italy
      • 9.2.4.3.1. By Source
      • 9.2.4.3.2. By Application
      • 9.2.4.3.3. By Distribution Channel
      • 9.2.4.4. France
      • 9.2.4.4.1. By Source
      • 9.2.4.4.2. By Application
      • 9.2.4.4.3. By Distribution Channel
      • 9.2.4.5. Spain
      • 9.2.4.5.1. By Source
      • 9.2.4.5.2. By Application
      • 9.2.4.5.3. By Distribution Channel
      • 9.2.4.6. Belgium
      • 9.2.4.6.1. By Source
      • 9.2.4.6.2. By Application
      • 9.2.4.6.3. By Distribution Channel
      • 9.2.4.7. Russia
      • 9.2.4.7.1. By Source
      • 9.2.4.7.2. By Application
      • 9.2.4.7.3. By Distribution Channel
      • 9.2.4.8. The Netherlands
      • 9.2.4.8.1. By Source
      • 9.2.4.8.2. By Application
      • 9.2.4.8.3. By Distribution Channel
      • 9.2.4.9. Rest of Europe
      • 9.2.4.9.1. By Source
      • 9.2.4.9.2. By Application
      • 9.2.4.9.3. By Distribution Channel

10. Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market

  • 10.1. Market Size & Forecast, 2019-2031
    • 10.1.1. By Value (USD Billion)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Source
    • 10.2.2. By Application
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
      • 10.2.4.1. China
      • 10.2.4.1.1. By Source
      • 10.2.4.1.2. By Application
      • 10.2.4.1.3. By Distribution Channel
      • 10.2.4.2. India
      • 10.2.4.2.1. By Source
      • 10.2.4.2.2. By Application
      • 10.2.4.2.3. By Distribution Channel
      • 10.2.4.3. Japan
      • 10.2.4.3.1. By Source
      • 10.2.4.3.2. By Application
      • 10.2.4.3.3. By Distribution Channel
      • 10.2.4.4. South Korea
      • 10.2.4.4.1. By Source
      • 10.2.4.4.2. By Application
      • 10.2.4.4.3. By Distribution Channel
      • 10.2.4.5. Australia and New Zealand
      • 10.2.4.5.1. By Source
      • 10.2.4.5.2. By Application
      • 10.2.4.5.3. By Distribution Channel
      • 10.2.4.6. Indonesia
      • 10.2.4.6.1. By Source
      • 10.2.4.6.2. By Application
      • 10.2.4.6.3. By Distribution Channel
      • 10.2.4.7. Malaysia
      • 10.2.4.7.1. By Source
      • 10.2.4.7.2. By Application
      • 10.2.4.7.3. By Distribution Channel
      • 10.2.4.8. Singapore
      • 10.2.4.8.1. By Source
      • 10.2.4.8.2. By Application
      • 10.2.4.8.3. By Distribution Channel
      • 10.2.4.9. Vietnam
      • 10.2.4.9.1. By Source
      • 10.2.4.9.2. By Application
      • 10.2.4.9.3. By Distribution Channel
      • 10.2.4.10. Rest of APAC
      • 10.2.4.10.1. By Source
      • 10.2.4.10.2. By Application
      • 10.2.4.10.3. By Distribution Channel

11. Latin America Monoclonal Antibody (mAb) Therapeutics Market

  • 11.1. Market Size & Forecast, 2019-2031
    • 11.1.1. By Value (USD Billion)
  • 11.2. Market Share & Forecast
    • 11.2.1. By Source
    • 11.2.2. By Application
    • 11.2.3. By Distribution Channel
    • 11.2.4. By Country
      • 11.2.4.1. Brazil
      • 11.2.4.1.1. By Source
      • 11.2.4.1.2. By Application
      • 11.2.4.1.3. By Distribution Channel
      • 11.2.4.2. Mexico
      • 11.2.4.2.1. By Source
      • 11.2.4.2.2. By Application
      • 11.2.4.2.3. By Distribution Channel
      • 11.2.4.3. Argentina
      • 11.2.4.3.1. By Source
      • 11.2.4.3.2. By Application
      • 11.2.4.3.3. By Distribution Channel
      • 11.2.4.4. Peru
      • 11.2.4.4.1. By Source
      • 11.2.4.4.2. By Application
      • 11.2.4.4.3. By Distribution Channel
      • 11.2.4.5. Rest of LATAM
      • 11.2.4.5.1. By Source
      • 11.2.4.5.2. By Application
      • 11.2.4.5.3. By Distribution Channel

12. Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market

  • 12.1. Market Size & Forecast, 2019-2031
    • 12.1.1. By Value (USD Billion)
  • 12.2. Market Share & Forecast
    • 12.2.1. By Source
    • 12.2.2. By Application
    • 12.2.3. By Distribution Channel
    • 12.2.4. By Country
      • 12.2.4.1. Saudi Arabia
      • 12.2.4.1.1. By Source
      • 12.2.4.1.2. By Application
      • 12.2.4.1.3. By Distribution Channel
      • 12.2.4.2. UAE
      • 12.2.4.2.1. By Source
      • 12.2.4.2.2. By Application
      • 12.2.4.2.3. By Distribution Channel
      • 12.2.4.3. Qatar
      • 12.2.4.3.1. By Source
      • 12.2.4.3.2. By Application
      • 12.2.4.3.3. By Distribution Channel
      • 12.2.4.4. Kuwait
      • 12.2.4.4.1. By Source
      • 12.2.4.4.2. By Application
      • 12.2.4.4.3. By Distribution Channel
      • 12.2.4.5. South Africa
      • 12.2.4.5.1. By Source
      • 12.2.4.5.2. By Application
      • 12.2.4.5.3. By Distribution Channel
      • 12.2.4.6. Nigeria
      • 12.2.4.6.1. By Source
      • 12.2.4.6.2. By Application
      • 12.2.4.6.3. By Distribution Channel
      • 12.2.4.7. Algeria
      • 12.2.4.7.1. By Source
      • 12.2.4.7.2. By Application
      • 12.2.4.7.3. By Distribution Channel
      • 12.2.4.8. Rest of MEA
      • 12.2.4.8.1. By Source
      • 12.2.4.8.2. By Application
      • 12.2.4.8.3. By Distribution Channel

13. Competitive Landscape

  • 13.1. List of Key Players and Their Offerings
  • 13.2. Global Monoclonal Antibody (mAb) Therapeutics Company Market Share Analysis, 2024
  • 13.3. Competitive Benchmarking, By Operating Parameters
  • 13.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships)

14. Impact of Escalating Geopolitical Tensions on Global Monoclonal Antibody (mAb) Therapeutics Market

15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 15.1. F. Hoffmann-La Roche Ltd
  • 15.2. Novartis AG
  • 15.3. Johnson & Johnson Services, Inc.
  • 15.4. GlaxoSmithKline plc
  • 15.5. Merck & Co., Inc.
  • 15.6. Amgen Inc
  • 15.7. Bristol Myers Squibb Company (US)
  • 15.8. Merck & Co Inc
  • 15.9. AstraZeneca plc
  • 15.10. Sanofi
  • 15.11. Bayer AG
  • 15.12. Eli Lilly and Company
  • 15.13. Thermo Fisher Scientific Inc
  • 15.14. Other Prominent Players

16. Key Strategic Recommendations

17. Research Methodology

  • 17.1. Qualitative Research
    • 17.1.1. Primary & Secondary Research
  • 17.2. Quantitative Research
  • 17.3. Market Breakdown & Data Triangulation
    • 17.3.1. Secondary Research
    • 17.3.2. Primary Research
  • 17.4. Breakdown of Primary Research Respondents, By Region
  • 17.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable